

1 **Bioinfo-pharmacology: the example of therapeutic hypothermia**

2

3

Fei Liu^{1,2,3,#}; Xiangkang Jiang^{1,2,3}, Mao Zhang^{1,2,3,*}

4

5 Author affiliations:

6 1. Department of Emergency Medicine, Second Affiliated Hospital of Zhejiang University,

7 Hangzhou 310009, Zhejiang Province, China.

8 2. Institute of Emergency Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province,

9 China.

10 3. Key Laboratory of The Diagnosis and Treatment of Severe Trauma and Burn of Zhejiang

11 Province, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.

12

13 #The first 1 author is the first author.

14 * corresponding author: Prof. Mao Zhang

15 Email: zjzk@zju.edu.cn

16 Telephone: +86 13757119125

17

18 **Declaration**

19 **Ethics approval and consent to participate.**

20 Not applicable.

21

22 **Consent for publication**

23 All authors allow the publication of this article.

24

25 **Availability of data and materials**

26 All the data that support the findings of this study are available for email from authors.

27

28 **Competing interests**

29 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
The authors have declared that they have no conflicts or interests.

30

31 **Funding**

32 The authors have stated that no such relationships exist.

33

34 **Authors' contributions**

35 FL designed the research and wrote the article. XJ drew the pictures. ZM modified the article and
36 analyzed the data.

37

38 **Acknowledge**

39 We thank Zaizai Cao, Xiangjie Lin, and Yuanyuan Hao for the algorithm discussion.

40

41

42

43

44 **Abstract**

45 Computer-aided drug discovery (CADD) is a widely used method for drug discovery
46 with many successes. Meanwhile, CADD has the limitation of analyzing multi-level
47 scores such as docking results of multiple proteins with multiple drugs. We propose a
48 method of PageRank to solve the problem. This method can make a comprehensive
49 ranking based on multi-level scores. Then we take an example of therapeutic
50 hypothermia (TH). Three levels of TH data were used in the article: the log₂
51 foldchange (logFC) of proteins, the relative expression values of mRNA, and the
52 docking scores of proteins and molecules. After calculation, we get the
53 comprehensive drug rank and drug combination rank of each group of TH, which
54 means we can generate the rank of drug directly from bioinformatics. Based on this
55 method, we raised the concept of bioinfo-pharmacology. Given the high rationality
56 and compatibility of bioinfo-pharmacology, it can effectively enhance popular drug
57 discovery techniques such as the docking or pharmacophore model. Besides, it could
58 advance the application of precision medicine.

59

60 **Keywords:** computer-aided drug discovery (CADD); precision medicine; Therapeutic
61 hypothermia; virtual screening;

62

63

64

65

66 **Introduction**

67 Drug discovery is an expensive and time-demanding process that faces many
68 challenges, including low hit discovery rates for high-throughput screening, among
69 many others.[1,2] Methods of computer-aided drug discovery (CADD) can
70 significantly speed up the pace of such screening and reduce the cost. Until now,
71 CADD has achieved important results. [3–5]

72 Meanwhile, CADD also has limitations. Researchers can only get the best match for a
73 particular target (drug development), or the best match for a particular molecule
74 (network pharmacology[6]). As a result, most pharmacological studies currently work
75 on a single target. However, according to bioinformatics databases,
76 diseases/treatments exist multiple targets, which generate complex regulation
77 functions, in the different stages of diseases/treatments.[7]

78 Take therapeutic hypothermia as an example. Therapeutic hypothermia (TH) can limit
79 the degree of some kinds of injuries in randomized trials[8] and animal
80 experiments[9], and is even the only effective method for some diseases especially
81 hypoxic-ischemic encephalopathy (HIE). HIE often causes severe neurological
82 sequelae, which is the main reason for the poor prognosis of patients with stroke,
83 shock, carbon monoxide poisoning, cerebral hemorrhage, and cardiac arrest.[10–12]

84 In the research based on TH, cold shock proteins especially cold-induced RNA
85 binding protein (CIRP) show high expression [13] and rapid response [14]. CIRP has
86 been shown to promote the translation of genes involved in DNA repair [15,16],
87 telomerase maintenance[17], and genes associated with the translational
88 machinery[18].

89 However, if CIRP leaks to the intercellular substance with cell swelling and rupture, it
90 will become a harmful protein. Extracellular CIRP (eCIRP) showed a strong pro-
91 inflammatory effect, leading to a heavier hypoxic injury.[19,20] Because of the habit
92 of clinical medication, we cannot determine whether there are drugs that affect the
93 therapeutic effect before and after the beginning of TH.

94 With the development of protein prediction technologies, especially AlphaFold2[21]

95 and RoseTTAFold[22], we can obtain the three-dimensional structure of proteins
96 more quickly and accurately. All target proteins' structures can be predicted, and their
97 best antagonists can be obtained by molecular docking. However, there is no
98 technology for comprehensively ranking the cross-level data of numerical evaluation.
99 To solve the complex function differences by temporal and spatial distribution
100 differences of proteins, we use personalization-weight-PageRank to rank drugs
101 targeting proteins predicted by AlphaFold2 and RoseTTAFold at different groups to
102 predict the best drugs or drug combinations for each group. Based on these, we came
103 up with the concept of bioinfo-pharmacology.

104 **Method**

105 Experiment design

106 As shown in Figure 1, the representative experiment of bioinfo-pharmacology is
107 divided into 5 processes: 1. Protein or mRNA chosen by bioinformatics analysis; 2.
108 Protein and drugs 3D structure acquisition and prediction; 3. Proteins' active sites
109 prediction; 4. Drug/molecular group evaluation with target proteins; 5. PageRank of
110 docking results, protein logFC, and mRNA expression. The experiment of animals or
111 cells is referred by authors, but not forced. The biggest difference from previous
112 studies is PageRank.

113

114 The data source of bioinformatics analysis

115 We retrieved the original data of mRNA expression under hypothermia treatment from
116 the website of The National Center for Biotechnology Information (NCBI)
117 (GSE54229). The research was reported by Sten et.al.[14] In their research, mouse
118 embryonic fibroblasts were exposed to mild hypothermia (32°C) or normothermia
119 (37°C) to gain the transcription response induced by hypothermia.

120

121 Expression Profile Analysis

122 The log₂ fold-change (log₂FC) and p-value were calculated for the normothermia
123 group. Top 3 log₂FC mRNA with q-value < 0.05 were selected from each group to
124 enter the next step. If there exists mRNA with failed protein structure prediction, the
125 mRNA would be skipped.

126 R 3.6.1 was used to detect differential expressed compared to matched normothermia
127 samples. The clustering of genes was calculated by the “dist” and “hclust” function of
128 R. The visualization of gene expression and clustering is performed by the
129 “dendextend” package.

130

131 3D Data of proteins and small molecular drugs

132 All proteins were first searched on PubMed to see if there was protein clipping like

133 cleaved caspase-3[23].

134 Then the 3D structures of proteins were firstly searched from Protein Data Bank
135 (PDB), which is used for biological-related ligand-protein interaction. In this article,
136 no protein structure is listed on the PDB website. All the protein structures were
137 predicted by AlphaFold2 and RoseTTAFold.

138 AlphaFold2 is developed by Google and is the champion of the 14th Critical
139 Assessment of Structure Prediction (CASP14). In August 2021, AlphaFold submitted
140 a structure prediction database for all proteins. RoseTTAFold is based on the Rosetta
141 software which is designed for macromolecular modeling, docking, and design[24]
142 RoseTTAFold also has good application[25] in the research of protein structure
143 prediction. Finally, protein structures with fewer irregular regions will be selected for
144 the next step.

145 The 3D structures of 8,697 drugs (DrugBank, 5.1.8) were downloaded from
146 DrugBank Online (<https://go.drugbank.com/>). Approved, experimental, nutraceutical,
147 and investigational drugs by Food and Drug Administration (FDA) are included. We
148 split each drug molecule into a PDBQT-format file and minimized the energy
149 separately for docking with proteins.

150

151 Visualize evolutionary conservation and active site prediction

152 Visualize evolutionary conservation was performed by the ConSurf server[26]. In a
153 typical ConSurf application, through BLASTed[27] against the UNIREF-90
154 database[28] and aligning using MAFFT[29], the evolutionarily conserved positions
155 are analyzed by the Rate4Site algorithm.

156 Then, the Consensus approach-D (COACH-D) [30] was used to predict the active site
157 of target proteins. The COACH-D use five different methods to predict the binding
158 sites of protein ligands. Four of these methods are COFAC-TOR[31], FINDSITE[32],
159 TM-SITE[33], and S-SITE[33]. These methods predict binding sites by matching the
160 query structure and sequence with the ligand-binding template in BioLiP[34], which
161 is a semi-manual functional database[35] based on the PDB.

162

163 Virtual screening of potential compounds

164 To evaluate the hit compounds obtained from DrugBank and calculate their
165 interaction and binding posture in the active site of target proteins, the molecular
166 docking method was carried out through QuickVina 2[36]. QuickVina 2 uses the
167 calculation of shape and electrostatic potential similarity of binding pockets to select
168 molecules, which may exhibit binding patterns like those of binding pockets.
169 3D files of target proteins were dehydrated, hydrogenated. Then proteins were saved
170 as PDBQT files using AutoDock. AutoDock assisted in assigning Gasteiger charges
171 and adding polar hydrogen atoms to both the proteins and the compounds.

172

173 Molecular dynamics simulation

174 The molecular dynamics (MD) simulation was performed by Gromacs[37]. Firstly, a
175 protein-drug complex was prepared, including adding hydrogenation and balancing
176 charge. Then, we add a solvent so that the target protein and drug small molecules are
177 coated. The forcefield was Chemistry at HARvard Macromolecular Mechanics 36
178 (CHARMm 36). The simulation time is set as 50ns for the speed of calculation. The
179 simulation temperature is 309.15K (36°C) and the pressure is 1 atm. Root mean
180 square deviation (RMSD) and root mean square fluctuation (RMSF) were calculated
181 based on the first frame.

182

183 Personalization-weight-PageRank

184 We use personalization-weight-PageRank to rank cross level data. PageRank is a
185 comprehensive rank algorithm designed by Google and named after Larry Page.[38] It
186 is one of the most famous ranking algorithms of network nodes based on Markov
187 process. PageRank has been applied in medical domains with success.[39,40]
188 Personalization and weight represent 3 different levels of score data. The weight of
189 PageRank allows all nodes to be initially assigned different weights/probabilities.[41]
190 In this article, the weights of rank were set to docking values of proteins and drugs.

191 The higher the docking value, the higher the connection rate of the complex.
192 Personalization of PageRank reinforces the connection intensity between the nodes,
193 which makes the result more personalized and realistic[42]. In this article,
194 personalization is influenced by protein functions. If the protein performs a negative
195 influence such as promoting apoptosis, the personalization will be calculated by
196 $2^{(\text{fold change})}$ to ensure they are more than 1. Meanwhile, if the protein plays a
197 positive role in the group, the personalization will be set as $1/(\text{fold change} + 1)$ to less
198 than 1. The personalization values of all the drugs are set to 0 to prevent iterations of
199 the drugs themselves from going wrong.

200 The calculation process is like putting all proteins and all drugs in the solution, then
201 simulating the connections between all proteins and drugs by calculation. The
202 damping factor is set to 0.85 to simulate the metabolism of proteins and drugs.

203 The whole calculation is based on Python 3.8.10. The relating python libraries include
204 NetworkX, Pandas, and NumPy. We use Pandas and NumPy to import all the docking
205 data into a matrix for PageRank calculating. The protein expression value is then
206 imported by the PageRank personalization parameter of NetworkX. Lastly, we can get
207 a comprehensive ranking of drugs.

208

209 Prediction and Rank of combined pharmacotherapy

210 In addition to the comprehensive ranking of drugs, we also try to generate the rank of
211 drug combinations. Similarly, the calculation places all drugs of combination and
212 target proteins in a solution to bind free.

213 First, all drugs will be grouped according to the docking results of drugs in each
214 combination. In this article, to reduce the amount of calculation, we selected the
215 TOP20 drugs of each protein to include in the drug combination pool. Then, all the
216 combinations were performed personalization-weight-PageRank against all protein
217 targets. The sum of each score of all drugs in the combination is the final score of the
218 combination. Lastly, we get the rank of combinations.

219 To make the distribution of combinations more clear, we propose drug-protein-

220 expression fit score (DPEFS) to show the data distribution pattern. The calculation is
221 as follows: The PageRank values of all proteins were summed by multiplying logFC,
222 then divided by the total PageRank values of drugs, and finally divided by the
223 PageRank values of specific proteins for standardized calculation. It is used for
224 standardized calculation for comparing different combinations.
225 DPEFS evaluates the combination by referring to the protein expression trend. The
226 higher the DPEFS, the better the fitness. In actual drug design, DPEFS is relatively
227 high and PageRank score is relatively low, indicating that drugs of combination are
228 relatively moderate, which suggests a negative outcome. All code can be found in
229 GitHub (<https://github.com/FeiLiuEM/PageRank-weight-drug>).

230 **Result**

231 Expression analysis and clustering of hypothermia

232 Figure 2 shows the expressions of different mRNA of different groups after
233 hypothermia. From the inside to the outside, the rings were divided into hypothermia
234 0.5h group, hypothermia 1H group, hypothermia 2H group, hypothermia 4H group,
235 hypothermia 8h group, and hypothermia 18h group.

236 As shown in Table 1, in each group, we selected the top 3 expression protein targets.

237 In the Hypothermia 0.5h group, the target proteins are circadian-associated
238 transcriptional repressor (CIART), Glutathione-specific gamma-
239 glutamylcyclotransferase 1 (CHAC1), and Uridine diphosphate glucose
240 pyrophosphatase nudix hydrolase 22 (NUDT22). The target proteins of the
241 Hypothermia 1h group are CHAC1, corneodesmosin (CDSN), and Nuclear receptor
242 subfamily 1 group D member 1 (NR1D1). The target proteins of the Hypothermia 2h
243 group are cold-induced RNA-binding protein (CIRP), armadillo repeat-containing X-
244 linked protein 5 (ARMCX5), and coiled-coil domain-containing protein 122
245 (CCDC122). The target proteins of the Hypothermia 4h group are CIRP, receptor
246 activity-modifying protein 3 (RAMP3), and carcinoembryonic antigen-related cell
247 adhesion molecule 1 (CEACAM1). The target proteins of the Hypothermia 4h group
248 are the same: CIRP, RAMP3, and NAD(P)H dehydrogenase [quinone] 1 (NQO1).

249 Within the targets, CHAC1 could enhance apoptosis[43]. NUDT22 is an Mg^{2+} -
250 dependent UDP-glucose and UDP-galactose hydrolase[44], while high glucose shows
251 a negative effect in HIE like stroke[45]. CCDC122 potentially pro-inflammatory[46].
252 CIRP can effectively reduce cell death in the early stage of hypothermia therapy.
253 However, it has a strong pro-inflammatory effect outside the cell, leading to cell
254 killing. There is no definitive research on the timing of this shift. Referring to the
255 previous article[47], we conservatively believed that CIRP could be identified as a
256 negative protein from the 8H group. CEACAM1[48] and NQO1[49] promote
257 apoptosis. All the other targets are shown protective effects or don't have enough data.
258 The personalization values were calculated in Table 1. All the structures of target

259 proteins in Figure 3 were obtained by the rules in the section of Materials and
260 Methods.

261

262 Visualize evolutionary conservation and Structure-Function Relationship-Based
263 Binding Site Prediction

264 The conservation analysis of all the target proteins was listed in Figure 4A-K. The
265 redder the amino acid, the higher possibility the amino acid sequence with function.
266 Then we identified its structure-function relationship by the COACH-D server. The
267 results showed a familiar result of conservation analysis listed in Figure 4L-V. As
268 shown in Table 2, the range around 3-5 Å of the active site was used for the setting of
269 the receptor pocket of the target proteins that were used for virtual screening.

270

271 Virtual Screening of target proteins' Antagonists

272 We utilized the virtual screening technique to identify potential antagonists exhibiting
273 an adequate binding affinity. We started with a chemical database consisting of 8,697
274 drug molecules and isolated a set of compounds satisfying the threshold of a high
275 docking score. The results of the best match complexes are shown in Figure 5 and all
276 the results are listed in the Additional file Table 1.

277

278 MD Simulations and Binding Free Energy Analysis

279 We performed MD simulation of 11 complexes to measure the stability of the protein-
280 ligand complex. RMSD (root-mean-square deviation) profiles of the protein are
281 shown in Figure 6A, which indicates that all systems were relatively stable during the
282 entire simulation run. Moreover, RMSF profiles of protein are measured to evaluate
283 the moving of each amino acid. All proteins are available for further analysis (Figure
284 6B).

285 The RMSD of drug atoms was also conducted to predict the stability of the atoms in
286 docked complexes (Figure 6C). Most compounds exhibited a consistently low RMSD,
287 suggesting that these compounds formed stable complexes.

288

289 Drug rank of TH in different groups

290 We rank all drugs by PageRank. First, we PageRank all the drugs and get the results

291 in table3. 2-drug-combinations are ranked in Table 4 and 3-drug-combinations in the

292 additional file Table 2. For comprehensive rank, the results of PageRank were listed.

293 For drug-combination ranks, the percentages of each drug's value in the combination

294 were calculated. And DPEFS was calculated for analyzing the distribution differences

295 of drug combinations.

296

297 **Discussion**

298 In this paper, a new pharmacological method — bioinfo-pharmacology is proposed,
299 using therapeutic hypothermia as an example. By bioinformatics analysis, protein
300 structure prediction, and PageRank, we provide a direct bridge between
301 symptom/treatment and drug design.

302 AlphaFold2 and RoseTTAFold were used for protein structure prediction. And the
303 number of proteins selected by AlphaFold2 in this research was close to that of
304 RoseTTAFold. During the process of protein structure prediction, we found that for
305 some proteins, the structures predicted by RoseTTAFold have less irregular structure
306 than that of AlphaFold2. This may be due to the 2D distance map level transformed
307 and integrated by RoseTTAFold during neural network training[22], while
308 AlphaFold2 only paired structure database and genetic database. We also find a
309 phenomenon that the predicted protein structures were relatively unstable under
310 molecular dynamics simulation than preview reports of other protein structures
311 detected by X-ray.

312 The application of PageRank is suitable. First, the combination of drug molecules is a
313 memoryless stochastic process, which meets the qualifications of the Markov process.
314 Second, our method aims to simulate the binding process *in vivo*. The comprehensive
315 analysis involves free docking of proteins with all drugs. Drug combination analysis
316 is to put proteins and related drugs into the solution for docking.

317 Besides, the method has good compatibility for the wide compatibility of PageRank.
318 In theory, all the technologies with numerical results can be ranked by the method. In
319 this paper, for the lack of bioinformatics data of Therapeutic hypothermia, we only do
320 a basic analysis. If there is more data of the TH, the analysis of Weighted Gene
321 Coexpression Network Analysis (WGCNA)[50] or Gene Regulatory Networks
322 (GRN)[51] will be better because they could provide more plausible results of protein
323 list.

324 Meanwhile, pharmacophore models[52] can use bioinfo-pharmacology for highly
325 efficient drug design. After ranking, top-ranked pharmacophore fingerprints or

326 alignments could be linked together for good pharmacological effects. And ultimately,
327 improve the therapeutic effect of drugs, reduce toxic and side effects, improve the
328 success rate of clinical trials of new drugs, save drug research and development costs.
329 For the same reason, this method can also enhance network pharmacology and
330 chrono-pharmacology. Network pharmacology[6] focuses on the application of
331 protein network structures to improve drug discovery. By PageRank, the association
332 between protein network structures and different drugs can be more accurately
333 understood through comprehensive drug analysis of multiple targets rather than the
334 previous single target. Thus, it has a good promotion effect on traditional herbal
335 medicine research. In traditional herbal medicine, there may be multiple drug
336 molecules in a single herb, and its complex multi-target problem can be efficiently
337 analyzed by new methods. Another influenced area is chrono-pharmacology. Chrono-
338 pharmacology[53] is expert in the adaptation and anticipation mechanisms of the
339 body concerning clock system regulation of various kinetic and dynamic pathways,
340 including absorption, distribution, metabolism, and excretion of drugs and nutrients.
341 By bioinfo-pharmacology, researchers can develop drugs for different time groups,
342 which will bring precision medicine to this kind of diseases.

343 Based on these potential improvements and high compatibility, we propose the
344 concept of bioinfo-pharmacology for its ability to directly apply bioinformatics for
345 drug discovery. Bioinfo-pharmacology is a method that uses bioinformatics, protein
346 structure prediction, and PageRank for drug design. The main feature is that multiple
347 targets target multiple molecules/pharmacophores. Overall, this approach builds a
348 bridge between disease/treatment and drug development, bringing up more
349 possibilities for future drug development.

350 This research has some defects. 1: For the speed of calculating, we only choose the
351 top 3 mRNAs and use the top 1 complex for MD simulation. Furthermore, the
352 duration of molecular dynamics simulation is set to 50ns. These operations mitigate
353 the rationality of the results relatively; 2. Theoretically, pharmacophore modeling has
354 a better improvement under PageRank. But considering the purpose of the article, we

355 use AutoDock to dock all the marketing drugs.

356 In summary, this paper proposes a new method of pharmacology—bioinfo-
357 pharmacology by PageRank. The results provide medical clues for the treatment of
358 TH. Besides, it can help the functional research of proteins at the molecular level for
359 experimental biologists. In addition, we can do drug combination analysis of drugs
360 similarly. The new approach could have a huge impact on precision medicine, drug
361 design, and traditional herbal medicine in the future.

362

363

364

365

366 **Reference**

- 367 **1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the**
368 **pharmaceutical industry: New estimates of R&D costs. J Health Econ.**
369 **2016;47:20–33.**
- 370 **2. Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early**
371 **drug discovery: Principles of early drug discovery. Br J Pharmacol.**
372 **2011;162:1239–49.**
- 373 **3. Li R, Li Y, Liang X, Yang L, Su M, Lai KP. Network Pharmacology**
374 **and bioinformatics analyses identify intersection genes of niacin and**
375 **COVID-19 as potential therapeutic targets. Brief Bioinform.**
376 **2021;22:1279–90.**
- 377 **4. Gandasi NR, Yin P, Omar-Hmeadi M, Ottosson Laakso E, Vikman**
378 **P, Barg S. Glucose-Dependent Granule Docking Limits Insulin**
379 **Secretion and Is Decreased in Human Type 2 Diabetes. Cell Metab.**
380 **2018;27:470-478.e4.**
- 381 **5. Cypionka A, Stein A, Hernandez JM, Hippchen H, Jahn R, Walla**
382 **PJ. Discrimination between docking and fusion of liposomes**
383 **reconstituted with neuronal SNARE-proteins using FCS. Proc Natl**
384 **Acad Sci U S A. 2009;106:18575–80.**
- 385 **6. Hopkins AL. Network pharmacology: the next paradigm in drug**
386 **discovery. Nat Chem Biol. 2008;4:682–90.**
- 387 **7. Wooller SK, Benstead-Hume G, Chen X, Ali Y, Pearl FMG.**
388 **Bioinformatics in translational drug discovery. Biosci Rep.**
389 **2017;37:BSR20160180.**
- 390 **8. Lascarrou J-B, Merdji H, Le Gouge A, Colin G, Grillet G,**
391 **Girardie P, et al. Targeted Temperature Management for Cardiac**
392 **Arrest with Nonshockable Rhythm. N Engl J Med. 2019;381:2327–37.**
- 393 **9. Kim JY, Kim JH, Park J, Beom JH, Chung SP, You JS, et al.**
394 **Targeted Temperature Management at 36 °C Shows Therapeutic**
395 **Effectiveness via Alteration of Microglial Activation and Polarization**
396 **After Ischemic Stroke. Transl Stroke Res. 2021;**
- 397 **10. Hosseini M, Wilson RH, Crouzet C, Amirhekmat A, Wei KS,**
398 **Akbari Y. Resuscitating the Globally Ischemic Brain: TTM and**
399 **Beyond. Neurother J Am Soc Exp Neurother. 2020;17:539–62.**
- 400 **11. Hazinski MF, Nolan JP, Aickin R, Bhanji F, Billi JE, Callaway**
401 **CW, et al. Part 1: Executive Summary: 2015 International Consensus**
402 **on Cardiopulmonary Resuscitation and Emergency Cardiovascular**
403 **Care Science With Treatment Recommendations. Circulation.**
404 **2015;132:S2-39.**
- 405 **12. Lemiale V, Dumas F, Mongardon N, Giovanetti O, Charpentier J,**
406 **Chiche J-D, et al. Intensive care unit mortality after cardiac arrest:**
407 **the relative contribution of shock and brain injury in a large cohort.**
408 **Intensive Care Med. 2013;39:1972–80.**
- 409 **13. Rosenthal L-M, Leithner C, Tong G, Streitberger KJ, Krech J,**
410 **Storm C, et al. RBM3 and CIRP expressions in targeted temperature**

- 411 **management treated cardiac arrest patients–A prospective single**
412 **center study. PloS One. 2019;14:e0226005.**
- 413 **14. Ilmjärvi S, Hundahl CA, Reimets R, Niitsoo M, Kolde R, Vilo J, et**
414 **al. Estimating differential expression from multiple indicators.**
415 **Nucleic Acids Res. 2014;42:e72.**
- 416 **15. Yang R, Zhan M, Nalabothula NR, Yang Q, Indig FE, Carrier F.**
417 **Functional significance for a heterogenous ribonucleoprotein A18**
418 **signature RNA motif in the 3'-untranslated region of ataxia**
419 **telangiectasia mutated and Rad3-related (ATR) transcript. J Biol**
420 **Chem. 2010;285:8887–93.**
- 421 **16. Haley B, Paunesku T, Protić M, Woloschak GE. Response of**
422 **heterogeneous ribonuclear proteins (hnRNP) to ionising radiation**
423 **and their involvement in DNA damage repair. Int J Radiat Biol.**
424 **2009;85:643–55.**
- 425 **17. Zhang Y, Wu Y, Mao P, Li F, Han X, Zhang Y, et al. Cold-**
426 **inducible RNA-binding protein CIRP/hnRNP A18 regulates**
427 **telomerase activity in a temperature-dependent manner. Nucleic**
428 **Acids Res. 2016;44:761–75.**
- 429 **18. Zhong P, Huang H. Recent progress in the research of cold-**
430 **inducible RNA-binding protein. Future Sci OA. 2017;3:FSO246.**
- 431 **19. Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T,**
432 **Iijima H, et al. Stress response protein cirp links inflammation and**
433 **tumorigenesis in colitis-associated cancer. Cancer Res. 2014;74:6119–**
434 **28.**
- 435 **20. Sakurai T, Kashida H, Komeda Y, Nagai T, Hagiwara S,**
436 **Watanabe T, et al. Stress Response Protein RBM3 Promotes the**
437 **Development of Colitis-associated Cancer. Inflamm Bowel Dis.**
438 **2017;23:57–65.**
- 439 **21. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger**
440 **O, et al. Highly accurate protein structure prediction with AlphaFold.**
441 **Nature. 2021;596:583–9.**
- 442 **22. Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S,**
443 **Lee GR, et al. Accurate prediction of protein structures and**
444 **interactions using a three-track neural network. Science.**
445 **2021;373:871–6.**
- 446 **23. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, et**
447 **al. Caspase-3-generated fragment of gelsolin: effector of**
448 **morphological change in apoptosis. Science. 1997;278:294–8.**
- 449 **24. Lemán JK, Weitzner BD, Lewis SM, Adolf-Bryfogle J, Alam N,**
450 **Alford RF, et al. Macromolecular modeling and design in Rosetta:**
451 **recent methods and frameworks. Nat Methods. 2020;17:665–80.**
- 452 **25. Humphreys IR, Pei J, Baek M, Krishnakumar A, Anishchenko I,**
453 **Ovchinnikov S, et al. Computed structures of core eukaryotic protein**
454 **complexes. Science. 2021;eabm4805.**
- 455 **26. Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, et**

- 456 **al. ConSurf 2016: an improved methodology to estimate and visualize**
457 **evolutionary conservation in macromolecules. *Nucleic Acids Res.***
458 **2016;44:W344-350.**
- 459 **27. Biegert A, Söding J. Sequence context-specific profiles for**
460 **homology searching. *Proc Natl Acad Sci U S A.* 2009;106:3770–5.**
- 461 **28. Suzek BE, Wang Y, Huang H, McGarvey PB, Wu CH, UniProt**
462 **Consortium. UniRef clusters: a comprehensive and scalable**
463 **alternative for improving sequence similarity searches. *Bioinforma***
464 **Oxf Engl. 2015;31:926–32.**
- 465 **29. Katoh K, Standley DM. MAFFT multiple sequence alignment**
466 **software version 7: improvements in performance and usability. *Mol***
467 **Biol Evol. 2013;30:772–80.**
- 468 **30. Wu Q, Peng Z, Zhang Y, Yang J. COACH-D: improved protein-**
469 **ligand binding sites prediction with refined ligand-binding poses**
470 **through molecular docking. *Nucleic Acids Res.* 2018;46:W438–42.**
- 471 **31. Roy A, Yang J, Zhang Y. COFACTOR: an accurate comparative**
472 **algorithm for structure-based protein function annotation. *Nucleic***
473 **Acids Res. 2012;40:W471-477.**
- 474 **32. Brylinski M, Skolnick J. A threading-based method (FINDSITE)**
475 **for ligand-binding site prediction and functional annotation. *Proc***
476 **Natl Acad Sci U S A. 2008;105:129–34.**
- 477 **33. Yang J, Roy A, Zhang Y. Protein-ligand binding site recognition**
478 **using complementary binding-specific substructure comparison and**
479 **sequence profile alignment. *Bioinforma Oxf Engl.* 2013;29:2588–95.**
- 480 **34. Yang J, Roy A, Zhang Y. BioLiP: a semi-manually curated**
481 **database for biologically relevant ligand-protein interactions. *Nucleic***
482 **Acids Res. 2013;41:D1096-1103.**
- 483 **35. Rose PW, Prlić A, Altunkaya A, Bi C, Bradley AR, Christie CH, et**
484 **al. The RCSB protein data bank: integrative view of protein, gene**
485 **and 3D structural information. *Nucleic Acids Res.* 2017;45:D271–81.**
- 486 **36. Alhossary A, Handoko SD, Mu Y, Kwoh C-K. Fast, accurate, and**
487 **reliable molecular docking with QuickVina 2. *Bioinforma Oxf Engl.***
488 **2015;31:2214–6.**
- 489 **37. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE,**
490 **Berendsen HJC. GROMACS: fast, flexible, and free. *J Comput***
491 **Chem. 2005;26:1701–18.**
- 492 **38. Page L, Brin S, Motwani R, Winograd T. The PageRank Citation**
493 **Ranking: Bringing Order to the Web. [Internet]. Stanford InfoLab;**
494 **1999 Nov. Report No.: 1999–66. Available from:**
495 **<http://ilpubs.stanford.edu:8090/422/>**
- 496 **39. Kalecky K, Cho Y-R. PrimAlign: PageRank-inspired Markovian**
497 **alignment for large biological networks. *Bioinforma Oxf Engl.***
498 **2018;34:i537–46.**
- 499 **40. Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends**

500 **in the development of miRNA bioinformatics tools. *Brief Bioinform.***
501 **2019;20:1836–52.**

502 **41. Xing W, Ghorbani A. Weighted PageRank algorithm. *Proc***
503 **Second Annu Conf Commun Netw Serv Res 2004. 2004. p. 305–14.**

504 **42. Haveliwala T, Kamvar S, Jeh G. An Analytical Comparison of**
505 **Approaches to Personalizing PageRank [Internet]. Stanford; 2003**
506 **Jun. Report No.: 2003–35. Available from:**
507 **<http://ilpubs.stanford.edu:8090/596/>**

508 **43. Mungrue IN, Pagnon J, Kohannim O, Gargalovic PS, Lulis AJ.**
509 **CHAC1/MGC4504 is a novel proapoptotic component of the**
510 **unfolded protein response, downstream of the ATF4-ATF3-CHOP**
511 **cascade. *J Immunol Baltim Md* 1950. 2009;182:466–76.**

512 **44. Carter M, Jemth A-S, Carreras-Puigvert J, Herr P, Martínez**
513 **Carranza M, Vallin KSA, et al. Human NUDT22 Is a UDP-**
514 **Glucose/Galactose Hydrolase Exhibiting a Unique Structural Fold.**
515 ***Struct Lond Engl* 1993. 2018;26:295-303.e6.**

516 **45. Zhang S, Zuo W, Guo X-F, He W-B, Chen N-H. Cerebral glucose**
517 **transporter: the possible therapeutic target for ischemic stroke.**
518 ***Neurochem Int.* 2014;70:22–9.**

519 **46. Leturiondo AL, Noronha AB, Mendonça CYR, Ferreira C de O,**
520 **Alvarado-Arnez LE, Manta FS de N, et al. Association of NOD2 and**
521 **IFNG single nucleotide polymorphisms with leprosy in the Amazon**
522 **ethnic admixed population. *PLoS Negl Trop Dis.* 2020;14:e0008247.**

523 **47. Denning N-L, Yang W-L, Hansen L, Prince J, Wang P. C23, an**
524 **oligopeptide derived from cold-inducible RNA-binding protein,**
525 **suppresses inflammation and reduces lung injury in neonatal sepsis.**
526 ***J Pediatr Surg.* 2019;54:2053–60.**

527 **48. Zhao C, Dang Z, Sun J, Yuan S, Xie L. Up-regulation of**
528 **microRNA-30b/30d cluster represses hepatocyte apoptosis in mice**
529 **with fulminant hepatic failure by inhibiting CEACAM1. *IUBMB Life.***
530 **2020;72:1349–63.**

531 **49. Feng Y, Cui R, Li Z, Zhang X, Jia Y, Zhang X, et al. Methane**
532 **Alleviates Acetaminophen-Induced Liver Injury by Inhibiting**
533 **Inflammation, Oxidative Stress, Endoplasmic Reticulum Stress, and**
534 **Apoptosis through the Nrf2/HO-1/NQO1 Signaling Pathway. *Oxid***
535 ***Med Cell Longev.* 2019;2019:7067619.**

536 **50. Langfelder P, Horvath S. WGCNA: an R package for weighted**
537 **correlation network analysis. *BMC Bioinformatics.* 2008;9:559.**

538 **51. Alexiou A, Chatzichronis S, Perveen A, Hafeez A, Ashraf GM.**
539 **Algorithmic and Stochastic Representations of Gene Regulatory**
540 **Networks and Protein-Protein Interactions. *Curr Top Med Chem.***
541 **2019;19:413–25.**

542 **52. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational**
543 **methods in drug discovery. *Pharmacol Rev.* 2014;66:334–95.**

544 **53. Tahara Y, Shibata S. Chrono-biology, chrono-pharmacology, and**

545

chrono-nutrition. J Pharmacol Sci. 2014;124:320–35.

546

547 Table 1. The target proteins of different groups.

Group	Target	logFC	Personalization
0.5h	CIART	0.46	0.42
	CHAC1	0.43	1.34
	NUDT22	0.40	1.32
1h	CDSN	0.52	0.41
	NR1D1	0.50	0.41
	CHAC1	0.50	1.41
2h	CIRP	0.80	0.36
	ARMCX5	0.66	0.39
	CCDC122	0.49	1.41
4h	CIRP	1.17	0.31
	RAMP3	0.91	0.35
	CEACAM1	0.87	1.82
8h	CIRP	1.57	2.97
	RAMP3	1.33	0.28
	NQO1	1.18	2.27
18h	CIRP	1.71	3.27
	NQO1	1.55	2.93
	RAMP3	1.32	0.29

548

549

550

551

552 Table 2. The docking parameters of target proteins.

Protein name	protein source	X	Y	Z	LEN-X	LEN-Y	LEN-Z
ARMCX5	RoseTTAFold	-7.06	31.20	-43.05	29.25	28.50	24.75
CDSN	RoseTTAFold	51.80	53.51	31.17	39.75	20.25	21.00
CEACAM1	AlphaFold2	-41.13	3.42	5.67	39.75	22.50	22.50
CHAC1	AlphaFold2	-3.04	-0.53	0.22	23.25	25.50	35.25
CIART	RoseTTAFold	36.79	-16.59	-36.23	28.50	38.25	22.50
CIRP	RoseTTAFold	14.48	2.86	-9.56	17.25	15.00	19.50
NQO1	AlphaFold2	-1.86	-16.32	-9.20	29.25	29.25	28.50
NR1D1	RoseTTAFold	0.34	35.70	10.28	39.75	25.50	24.75
NUDT22	AlphaFold2	10.08	-12.04	14.09	17.25	38.25	22.50
RAMP3	AlphaFold2	0.00	-10.93	-5.29	24.00	24.00	21.00
CCDC122	RoseTTAFold	119.27	23.34	8.09	36.00	47.25	47.25

553

554

555

556 Table 3. The comprehensive rank of drugs at different groups.

Gro up	Drug	weighted_personalized_PageRan k (*10⁻⁴)
h0.5 h	Fluzoparib	0.81
	Lorecivivint	0.80
	Vactosertib	0.80
h1h	Lorecivivint	0.81
	AC-430	0.81
	Raltegravir	0.80
h2h	Phthalocyanine	0.90
	Vazegepant	0.87
	Bemcentinib	0.86
h4h	Phthalocyanine 3-(2- AMINOQUINAZOLI N-6-YL)-4- METHYL-N-[3- (TRIFLUOROMETH YL)PHENYL]BENZ AMIDE	0.85
	Bemcentinib	0.84
	Phthalocyanine	0.87
h8h	MK-3207	0.86
	Lifirafenib	0.85
	Phthalocyanine	0.87
h18h	MK-3207	0.86
	Lifirafenib	0.85

557


558

Table 4. Rank of 2 drug combinations of different group.

	drug1	drug2	Pag- eRank value of drug1	per- centage	Pag- eRank value of drug2	per- centage	personal- ized_weight_PageRank	Drug- pro- tein- expres- sion fit score
h0. 5h	Lorecivivint	Fluzoparib	0.41	49.85	0.42	50.15	0.83	2.30
	Vactosertib	Fluzoparib	0.41	49.56	0.42	50.44	0.83	2.33
	2'-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate)	Fluzoparib	0.41	49.68	0.42	50.32	0.83	2.32
h1h	Lorecivivint	AC-430	0.41	49.67	0.42	50.33	0.83	4.36
	Lorecivivint	Raltegravir	0.42	50.12	0.41	49.88	0.83	4.40
	Lorecivivint	Vactosertib	0.42	50.21	0.41	49.79	0.83	4.37
h2h	Phthalocyanine	Vazegepant	0.42	51.42	0.40	48.58	0.82	4.65
	Phthalocyanine	Bemcentinib	0.43	51.84	0.40	48.16	0.82	4.71
	Phthalocyanine	Lifirafenib	0.43	52.28	0.39	47.72	0.82	4.64
h4h	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	CD564	0.41	50.25	0.41	49.75	0.82	1.60

	Adapalene	3-(2-AMINOQUINAZOLIN-6-YL)- 4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	0.41	49.90	0.41	50.10	0.82	1.60
	3-(2-AMINOQUINAZOLIN-6-YL)- 4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	Phthalocyanine	0.42	50.52	0.41	49.48	0.82	1.60
	Phthalocyanine	MK-3207	0.41	49.91	0.41	50.09	0.83	3.94
h8h	Phthalocyanine	Lifirafenib	0.42	50.17	0.41	49.83	0.83	3.93
	Lifirafenib	MK-3207	0.41	49.75	0.42	50.25	0.83	3.94
	Phthalocyanine	MK-3207	0.41	49.91	0.41	50.09	0.83	4.95
h18 h	Lifirafenib	MK-3207	0.41	49.77	0.42	50.23	0.83	4.95
	Phthalocyanine	Lifirafenib	0.42	50.14	0.41	49.86	0.83	4.94

1 Figure 1. Representative workflow for bioinfo-pharmacology drug design.



14 Figure 2. Circular visualization of expression patterns and clustering of hypothermia
15 treatment. Red indicates gene upregulation and blue indicates downregulation.

16

17

18

19

20

21

22

23

24

25

26

27

28

29


30

31


32

33

34




35 Figure 3. The 3D structures of target proteins. A. ARMCX5; B. CCDC; C. CDSN; D.
36 CEACAM1; E. CHAC1; F. CIART; G. CIRP; H. NQO1; I. NR1D1; J. NUDT22; K.
37 RAMP3.



47
48
49
50
51
52
53
54


55 Figure 4. The ConSurf analysis and predicted active sites of target proteins. The upper
56 11 pictures are ConSurf analysis results. The last 11 pictures are predicted active sites.
57 A&L. ARMCX5; B&M. CCDC; C&N. CDSN; D&O. CEACAM1; E&P. CHAC1;
58 F&Q. CIART; G&R. CIRP; H&S. NQO1; I&T. NR1D1; J&U. NUDT22; K&V.
59 RAMP3. The redder the amino acid, the more conservative it is. The greener the color,
60 the less conservative it is.



61

62

63 Figure 5. The best docking molecular for each protein. A. ARMCX5; B. CCDC; C.
64 CDSN; D. CEACAM1; E. CHAC1; F. CIART; G. CIRP; H. NQO1; I. NR1D1; J.
65 NUDT22; K. RAMP3.



66
67
68
69
70

71 Figure 6. The RMSD and RMSF of MD simulation. A. The RMSD of proteins. B. The
72 RMSF of proteins. C. The RMSD of each molecular of proteins.

73

74

75

76

